Anktiva Momentum: A Swing Trade Plan for ImmunityBio (IBRX)
ImmunityBio has a clearer regulatory path for ANKTIVA and expanding product revenue that justify a risk-on swing trade. The company still carries high valuation, negative cash flow, heavy short interest and legal overhangs. This trade targets upside into renewed regulatory progress while capping loss if momentum reverses.